Key Takeaways
- Volume growth strong, margin recovery elusive: Volume grew sequentially and YoY, with management confident of 20-30% volume growth for FY25, but EBITDA guidance was effectively withdrawn due to intense Chinese margin pressure and energy-segment volatility.
- China overcapacity is the dominant headwind: 70-80% of the product basket faces Chinese competition, and margins in non-discretionary segments are nowhere close to cycle averages, with recovery a "long road ahead."
- Energy application is a double-edged sword: A new, large, export-oriented business is driving volume and export share to 60%, but its crude-linked volatility and immature contract structures are a major source of earnings unpredictability.
- The CAPEX cycle is peaking: FY25 is the peak year for CAPEX, with a significant portion going into the Chlorotoluene value chain at the new Zone-IV site; a decline next year is expected to support ROCE improvement.
- What to watch next quarter: Whether management reinstates any EBITDA guidance after its promised 2-3 month observation period, and any signs of stabilization in energy-segment contract terms.
Margin Pressure & Competitive Landscape
- Chinese competition is structural and pervasive: 70-80% of the product basket faces Chinese competition, which has driven EBITDA per kg for many products below pre-COVID levels. The pressure is not confined to one chain but is broad-based across the portfolio.
- Non-discretionary segments are deeply depressed: Agrochemicals are showing "green shoots" in volumes, but margins remain far from cycle averages and are not expected to recover within one or two quarters. The company sees this as a long road ahead.
- Gross margin is volatile: Gross margin has swung from 41% to 36% to 40% to 38% in recent quarters, driven by raw material price swings in benzene and aniline, a changing product mix, and a shifting geographical footprint.
- Pass-through is not universal: While the benzene downstream portfolio retains pass-through pricing, the aniline downstream portfolio has a mix of raw-material-linked and market-exposed contracts, creating inherent volatility.
- Tier-2/3 customers remain a tactical necessity: As demand recovers, the company prioritizes Tier-1 customers, but still relies on Tier-2/3 customers, including in China, on a month-to-month basis to optimize inventory and production. The problem has not completely gone away.
Suyog Kotecha: "I think the pressure from China is actually not sort of going away and we have seen that across broader product portfolio, not in a specific chain, but across broader product portfolio, the pressure on margin is still very intense."
The Energy Application: Volume Driver & Earnings Risk
- A large but volatile new business: The energy application has scaled up significantly and is now a relatively large part of the portfolio, linked to crude, gasoline cracks, and naphtha cracks. This brings additional earnings volatility that the company is still learning to manage.
- Export share has shifted materially: The rise of the largely export-oriented energy application has pushed the company's export share from approximately 52% to 60%.
- Contract structuring is a work in progress: Management is on a "learning journey" in structuring contracts for this new segment and hopes to land at a win-win arrangement with counterparties in the next couple of quarters.
- Near-term significance, long-term moderation: Energy will remain a significant part of the application mix in the near term, but its share may moderate over 1-2 years as other segments recover.
Suyog Kotecha: "We are also figuring out how to write, structure these contracts and sort of this transaction. And we are going to go through that learning journey and hopefully in a span of next couple of quarters, we land at an arrangement which is a win-win for both sides."
Volume Growth & Demand Environment
- Broad-based volume momentum: Volume growth was driven by positive demand across pharma, polymers, additives, dyes and pigments, with small green shoots in agrochemicals. Growth is broad-based, not linked to one product; even the non-MMA portfolio showed 5-6% QoQ growth.
- SABIC contract at full capacity: The SABIC contract has ramped up significantly, with the plant now running at full capacity, indicating a demand pickup in polymer end applications.
- NCB and Nitrotoluene driven by structural demand: Volume growth in NCB and Nitrotoluene is attributed more to structural demand improvement in end markets than to better nitric acid availability.
- Bangladesh exposure is negligible: Direct exposure to the Bangladesh textile market is close to negligible, at less than 1% of the portfolio, with no red flags seen so far.
Project Pipeline & CAPEX
- FY25 is the peak CAPEX year: CAPEX is expected to peak in FY25 and decline significantly next year, with the bulk of remaining FY25 spend going into the Chlorotoluene value chain at Zone-IV.
- Nitrotoluene and Ethylation expansion on track: Nitrotoluene capacity is being expanded from ~30,000 to ~45,000 tons, and Ethylation capacity is being tripled from ~8,000-10,000 to ~25,000 tons, with commissioning expected by the end of the current quarter. Total CAPEX for these projects is ₹400-500 crore.
- Zone-IV greenfield is the next growth leg: Phase-wise commissioning is expected from next financial year, with the Chlorotoluene value chain forming a significant part of the business. The company plans to go significantly downstream into specialty derivatives with a portfolio of 40 different products.
- Utilization ramp-up is a multi-year story: The company targets 40-50% capacity utilization for Nitrotoluene and Ethylation within FY25, rising to 70-80% next year. Volume targets are achievable, but targeted margins in rupees per kg will take more time.
- UPL JV adds a new downstream avenue: The 50-50 JV (Augene Chemical) for amine derivatives targets commercial supplies by Q1 FY27, with peak annual revenue potential of ₹400-500 crore within 2-3 years. Products have no overlap with the existing business.
Suyog Kotecha: "We are not stopping at the first 2 steps in the chain. We have a portfolio of 40 different products as part of that investment and we will go significantly downstream into specialty derivatives."
Financial Health & ROCE
- EBITDA growth driven by operating leverage: Higher volumes led to operating leverage and a favorable product mix, contributing to EBITDA growth despite margin headwinds.
- Other expenses declined sequentially: Other expenses fell from ₹319 crore to ₹281 crore QoQ, driven by the non-repeat of annual employee benefit costs in Q4 and lower freight incidence from an increased share of business with the Middle East and Asia.
- Depreciation and interest costs remain elevated: Both remain higher due to the capitalization of projects, in line with prevailing interest rates.
- ROCE improvement expected as CAPEX declines: A large chunk of past CAPEX went into upgradation and reliability, not purely growth. Current and next-year CAPEX is predominantly growth-led, and management expects a decent uptick in ROCE as CAPEX peaks this year and declines next year.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Volume growth | 20% to 30% YoY volume growth for FY25 | Full FY25 |
| Nitrotoluene/Ethylation utilization | 40-50% capacity utilization | Within FY25 |
| Nitrotoluene/Ethylation utilization | 70-80% capacity utilization | Next financial year |
| CAPEX trajectory | FY25 is peak year; significantly lower CAPEX expected | Next financial year |
| UPL JV commercial supplies | Commercial supplies begin; peak revenue ₹400-500 crore within 2-3 years | Q1 FY27 |
| Zone-IV commissioning | Phase-wise commissioning begins | Next financial year |
| EBITDA guidance | Management will watch margin trends before committing; current guidance effectively withdrawn | Next 2-3 months |
| Energy contract structuring | Aims to land at a win-win arrangement | Next couple of quarters |
Key Metrics
| Metric | Q1 FY25 |
|---|---|
| Revenue | ₹2,012 cr, +28% YoY and +3% QoQ |
| Volume growth | ~6% QoQ, over 30% YoY |
| EBITDA | ₹311 cr, +55% YoY and +10% QoQ |
| PAT | ₹137 cr, +4% QoQ |
| Gross margin | 38%, vs 40% in Q4 FY24 and 41% in Q3 FY24 |
| Other expenses | ₹281 cr, down from ₹319 cr in Q4 FY24 |
| Nitro Chloro Benzene production | 19,503 MT, vs 17,293 MT in Q1 FY24 and 17,646 MT in Q4 FY24 |
| Nitrotoluene production | 7,637 MT, vs 9,320 MT in Q1 FY24 and 6,675 MT in Q4 FY24 |
| Hydrogenation output | 3,428 tons per month, vs 2,868 tons in Q1 FY24 and 3,389 tons in Q4 FY24 |
| PDA production | ~206 tons per month, vs 135 tons per month in Q1 FY24 |
| Export share | 60%, up from ~52% average last year |
| CAPEX spent in Q1 | ₹270 cr, out of ₹1,500-1,800 cr projected for FY25 |
| Debt level | ~₹3,300 cr, peak expected at ₹3,500-3,800 cr during FY25 |
| Product basket with direct China competition | 70% to 80% |
| Full-year volume growth target | 20% to 30% YoY |